|Company Name:||BOC Sciences Gold|
|Company Name:||J & K SCIENTIFIC LTD. |
|Synonyms:||N-METHYL-11-AZA-10-DEOXO-10-DIHYDROERYTHROMYCIN A;11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-tr;11-(4-DIMETHYLAMINO-3-HYDROXY-6-METHYL-TETRAHYDRO-PYRAN-2-YLOXY)-2-ETHYL-3,4,10-TRIHYDROXY-14-(5-HYDROXY-4-METHOXY-4,6-DIMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-3,5,6,8,10,12,13-HEPTAMETHYL-1-OXA-6-AZA-CYCLOPENTADECAN-15-ONE;9-DEOXO-9ALPHA-METHYL-9ALPHA-AZA-HOMOERYTHROMYCIN A;9-deoxo-9a-methyl-9a-aza-homoerythromycin a;AZITHROMYCIN;AZITHROMYCINE;1-oxa-6-azacyclopentadecan-15-one,13-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha|
|Product Categories:||Antibiotics;Antibiotic;Antibiotic Explorer;Intermediates & Fine Chemicals;Pharmaceuticals;API's;NeatsMore...Close...;1694 Pharmaceuticals&Personal Care Products;A - KAntibiotics;Antibacterial;Antibiotics A to;Antibiotics A-FAntibiotics;AntiviralAntibiotics;Chemical Structure Class;Interferes with Protein SynthesisAntibiotics;MacrolidesEPA;Mechanism of Action;Spectrum of Activity;veterinary medicine,soluble powder,preparation;Peptide Synthesis/Antibiotics;Pharmaceutical intermediate;Inhibitors|
|Azithromycin Chemical Properties|
|Melting point ||113-115°C|
|storage temp. ||Store at -20°C|
|Stability:||Stable. Incompatible with strong oxidizing agents.|
|CAS DataBase Reference||83905-01-5(CAS DataBase Reference)|
|EPA Substance Registry System||1-Oxa-6-azacyclopentadecan- 15-one, 13-[(2,6-dideoxy-3-C-methyl- 3-O-methyl-.alpha.-L-ribo- hexopyranosyl)oxy]-2-ethyl- 3,4,10-trihydroxy-3,5,6,8, 10,12,14-heptamethyl-11-[[ 3,4,6-trideoxy-3-(dimethylamino)-. beta.-D-xylo-hexopyranosyl] oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S, 13S,14R)-(83905-01-5)|
|Azithromycin Usage And Synthesis|
|The most commonly used antibiotics||Because the side effects of Azithromycin are less than Cephalosporins, now Azithromycin is the most commonly used antibiotics for bacterial infection-related diseases in our hospital clinic. This drug is a second generation semi-synthetic derivative of macrolide, whose structure is different from Erythromycin. It inserted a methyl-substituted nitrogen in 9a site of Erythromycin lactone ring, generating a 15-membered ring macrolide. |
The mechanism of action of Azithromycin is similar to Erythromycin. By binding to 50S subunit susceptible ribosome, Azithromycin inhibits protein synthesis which depends on RNA to show an antibacterial effect, retaining the antibacterial spectrum of typical Erythromycin. As for activity to chlamydia, Azithromycin is similar to Erythromycin. Compared with Erythromycin, antibacterial activity for gram-negative bacteria has been significantly improved, antibacterial activity for Haemophilus influenzae and Neisseria gonorrhoeae is more four times than Erythromycin, antimicrobial activity for Legionella bacteria is more about 2 times than Erythromycin, and antibacterial activity for Enterobacteriaceae is significantly stronger than Erythromycin. The MIC of most gram-negative bacteria is less than 1μg / ml. Staphylococcus aureus and Streptococcus pyogenes show cross-resistance on Azithromycin and Erythromycin. For toxoplasmosis and syphilis, Azithromycin also has a good role in the killing. Azithromycin is mainly used for respiratory tract infections, genitourinary tract infections, skin and soft tissue infections and sexually transmitted diseases which are caused by sensitive bacteria.
|Pharmacokinetics||It is rapidly absorbed after oral administration, and its bioavailability is 37%. After a single oral dose of 0.5g, the peak time is 2.5 to 2.6 hours, peak plasma concentration (Cmax) is 0.4 ~ 0.45mg / L. This product is widely distributed in the body, and concentrations in each tissue are up to 10 to 100 times of the blood concentration over the same period. The plasma concentrations are high in macrophages and fibroblasts , the former can transport Azithromycin to inflammation sites. After a single dose administration of the product, elimination half-life of plasma concentration is 35 to 48 hours, more than 50% of the administered dose is excreted in the bile duct in original shape, and after 72 hours administration about 4.5% is excreted in the urine in original shape. With increasing plasma concentrations, serum protein binding rate of this product decreased. When the plasma concentration is 0.02 μg / mL, serum protein binding rate is 15%; when the blood concentration is 2 μg / mL, serum protein binding rate is 7%.|
|Antibacterial spectrum||1. Gram-positive aerobic bacteria, such as Staphylococcus aureus, Streptococcus pyogenes (A group β- hemolytic streptococcus), Streptococcus pneumoniae, α- hemolytic Streptococci (Streptococcus viridans group) and the other Streptococcus, Diphtheria (rodlike) bacteria. |
2. Gram-negative aerobic bacteria, such as Haemophilus influenzae, Haemophilus parainfluenza, catarrhal bacteria, Acinetobacter, Yersinia, Legionella spp, Bordetella pertussis, parapertussis, Shigella, Pasteurella spp., Vibrio cholerae, Vibrio parahaemolyticus, Shiga topiramate o Aeromonas. The activities for Escherichia coli, Salmonella enteritidis, Salmonella typhi, Enterobacter, addicted to waterborne Aeromonas and Klebsiella are not the same, and sensitivity test is needed.
3. Anaerobic bacteria, such as Bacteroides spp., Clostridium perfringens, Lactococcus digestion, digestion Streptococcus, Fusobacterium, Propionibacterium acnes.
4. Sexually transmitted disease microorganisms, such as Chlamydia trachomatis, Treponema pallidum, Neisseria gonorrhoeae, Haemophilus Duke.
5. Other microorganisms, such as Borrelia burgdorferi (Lyme pathogens), Chlamydia pneumoniae, Mycoplasma hominis, Ureaplasma urea, bending genus, mononucleosis and Lee de bacilli.
Azithromycin shows cross-resistance for Gram-positive bacteria with Erythromycin-resistant and various strains of Staphylococcus aureus with methicillin-resistant, and Gram-positive bacteria such as Proteus, Serratia, Morgan bacteria, Pseudomonas aeruginosa are usually resistant to Azithromycin.
The above information is edited by the Chemicalbook of Liu Yujie.
|Indications||This product is suitable for the treatment of the following symptoms of infection caused by susceptible bacteria: |
1. For acute pharyngitis and acute tonsillitis caused by Streptococcus pyogenes and for nasosinusitis, acute otitis media, acute bronchitis, and acute exacerbation of chronic bronchitis caused by sensitive bacteria.
2. For pneumonia caused by Mycoplasma pneumonia, Streptococcus pneumonia and Haemophilus influenza.
3. For urethritis, cervicitis and pelvic inflammatory disease caused by chlamydia and non-multiple drug resistance Neisseria gonorrhoeae, and for simple genital infection caused by non-multiple drug resistance Neisseria gonorrhoeae (exclude co-infection of Misu spirochetes).
4. For skin and soft tissue infections caused by sensitive bacteria.
|Dosing instructions||1. The oral administration of drug should be in the 1 hour before meals or 2 hours after meals. |
2. Azithromycin injection should not be administered intramuscularly. Single intravenous infusion time should not be less than 60 minutes, and infusion concentration should not exceed 2mg / ml.
3. Solution preparation: Azithromycin is fully dissolved with the appropriate amount of water for injection, prepared a 100mg / ml solution. And then it is added into 250ml or 0.9% 500ml of sodium chloride injection or 5% glucose injection, finally formulated as 1-2mg / ml intravenous drip infusion.
4. If allergic reactions is happened during treatment, patients should be discontinued immediately. Like other antibiotics, superinfection symptoms caused by susceptible bacteria including fungi should be observed. If diarrhea symptom is appeared, it should be considered whether pseudomembranous colitis occur or not. In case of the establishment of the diagnosis, appropriate therapeutic measures should be took immediately, including maintenance of water and electrolyte balance, proteins supplement, etc.
5. If drug overdose reaction happens in medication, gastric lavage or general supportive therapy can be performed.
|Usage and dosage||Adult|
1. Community-acquired pneumonia: intravenous infusion for at least 2 days turning into oral administration, once 500 mg, 1 times a day, 7-10 day for a course.
2. For sexually transmitted diseases caused by Chlamydia trachomatis, Duke Haemophilus or sensitive Neisseria gonorrhoeae, only a single oral dose of 1g.
3. Pelvic inflammation disease: intravenous infusion for 1-2 days turning into oral administration, once 250 mg, 1 time a day, 7 day a course of treatment.
1.Community-acquired pneumonia: one 500mg, once a day, at least continuous medication for 2 days, followed by turning into oral administration. Usage and dosage see oral administration items.
2. Pelvic inflammatory disease: an adult once 500 mg, 1 times a day, 1-2 days of medication, using the drug for oral administration. Usage and dosage see oral administration items.
Renal insufficiency dose
Patients with mild renal insufficiency (creatinine clearance rate is greater than 40ml / min) are no need for dose adjustment.
Hepatic insufficiency dose
Patients with mild to moderate hepatic dysfunction are no need for dose adjustment.
Elderly dosage: Usage and dosage is same as adults.
1. General infections: total dose for children is 30 mg / kg, once 10 mg / kg, 1 times a day, consecutive administration for 3 days; or the first day 10 mg / kg, 2-5 days, once 5 mg / kg, 1 times a day, continuous administration for 5 days.
2. Otitis media and pneumonia: Day 1 10 mg / kg administered at draught, a day of maximum amount does not exceed 500 mg; 2-5 day, a day 5 mg / kg administered at draught,a day of maximum amount does not exceed 250 mg.
3. Pharyngitis and tonsillitis: a day 12 mg/kg administered at draught, continuous administration for 5 days. A day of maximum amount does not exceed 500 mg. Administration can also refer to the following table.
Children pharyngitis and tonsillitis (both 1 time a day)
Weight Age three days administration plan five days administration plan
15kg or less 1-3years old once 100 mg, continuous administration for 3 days
15-25kg 3-8 years old once 200 mg, continuous administration for 3 days. first day once 200mg，2-5 days, once 100 mg
26-35kg 9-12 years old once 300 mg, continuous administration for 3 days. first day once 300mg，2-5 days, once 150 mg
36-45kg 13-15 years old once 400 mg, continuous administration for 3 days. first day once 400mg，2-5 days, once 200 mg
45kg or more Usage and dosage is same as adults.
|Drug interactions||1. Azithromycin should not be taken with antacids containing aluminum or magnesium, which can be reduced by 30% of the peak plasma concentration of the product, but it has no impact on the overall bioavailability; If they must be combined the product should be administrated before one hour or after two hours taking these drugs. |
2. When Azithromycin combines with theophylline, concentrations of theophylline in plasma will increase, and plasma theophylline levels should be noted.
3. When Azithromycin combines with warfarin, prothrombin time should be checked.
4. When Azithromycin and the following drugs are used at the same time, it is recommended to closely observe patients: Digoxin: there have been reports that some macrolide antibiotics can reduce the intestinal metabolism of digoxin. So using two drugs at the same time, it should be noted that plasma concentration of digoxin show a possibility to increase. Ergotamine or dihydroergotamine: Acute ergot toxicity, symptoms are severe peripheral vasospasm and hypoesthesia (dysesthesia). Triazolam: by reducing the degradation of triazolam, it can enhance pharmacological effects of triazolam. Cytochrome P450 system metabolite drug一 increasing serum levels of carbamazepine, terfenadine, cyclosporine, cyclohexanone, phenobarbital, phenytoin.
5. Azithromycin combined with rifabutin will increase toxicity of the latter.
|Side effects||Patients are well tolerated to Azithromycin, incidence of adverse reactions is low. |
1. Gastrointestinal: after treatment, fear of food, abdominal pain, diarrhea, nausea, vomiting, abdominal distension (<1%), gastritis (<1%), mucositis (<1%), pseudomembranous colitis, etc. can occur, butthe incidence was significantly lower than Erythromycin; small number of patients using the drug even can cause stomatitis, oral candidiasis (<1%); rare tongue discoloration.
2. Liver: alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase, bilirubin, alkaline phosphatase may increase transiently. The drug has been reported to cause hepatitis and cholestatic jaundice; occasionally cause liver necrosis and liver failure, but the relationship of rare death with the drug has not been determined.
3. Neuropsychiatric system: headache (<1%), drowsiness (<1%). In addition, the relationship of dizziness, convulsions, paresthesia, increased activity, aggressive reactions, nervousness, anxiety, anxiety with the drug has not been determined.
4. Allergies: fever, rash, itching may occur. Side effects which are associated with the drug have not been determined, including urticaria, bronchospasm (<1%), photosensitivity, joint pain. Anaphylactic shock and angioedema are extremely rare. Severe cases may occur erythema multiforme, Stevens-Johnson syndrome and toxic epidermal dissolve and necrosis. Drug should be discontinued immediately, and take appropriate measures.
5. Blood: may have the reduction of white blood cells, neutropenia, thrombocytopenia.
6. Urogenital system: common vaginitis; it may have a transient increase in serum creatinine; the relationship of existence of interstitial nephritis and acute renal failure with the drug has not been determined.
7. Ear: patients taking Azithromycin had been hearing impairment, including hearing loss, tinnitus and (or) epicophosis, which is related to high-dose use of the drug and mostly reversible.
8. Local: when the injection, injection site pain and local inflammation may occur.
9. Cardiovascular system: the relationship of cardiac arrhythmia, ventricular tachycardia with the drug has not been determined.
10. Other: it is reported rarely that drug causes changes in taste (<1%).
|Precautions||1. Patients who are allergic to this product, Erythromycin or any other macrolide drug are contraindicated. |
2. Application for pregnant women should be fully weighed; application for lactating women requires careful consideration; efficacy and safety for treatment of age <6 months of pediatric otitis media, community-acquired pneumonia and age <2 years pharyngitis or tonsillitis in children have not been determined.
3. Patients with mild renal insufficiency (creatinine clearance rate> 40ml / min) are no need for dose adjustments, but for more serious patients with renal insufficiency, should be used with caution.
4. Since the hepatobiliary system is the main route of excretion of the product, patients with liver dysfunction should be used with caution. Severe liver disease should not be used. Regular follow-up liver function during treatment.
5. Food can affect the absorption of Azithromycin, so oral administration is needed at 1h before meals or after meals 2h.
6. During the treatment if allergy occurs (such as angioneurotic edema, skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis, etc.), patients should be discontinued immediately, and take appropriate measures. If patients appear diarrhea symptom, pseudomembranous colitis should be considered, if the diagnosis is determined, appropriate therapeutic measures should be took, including maintenance of water and electrolyte balance, proteins supplement, etc.
7. If suspected the combined anaerobic infectionsmerger anaerobic infections, Azithromycin should be combined with anti-anaerobic drugs during treatment of pelvic inflammatory disease.
|Clinical evaluation||Foreign reports compared the Azithromycin with Cefaclor in treatment of acute lower respiratory tract infection. Azithromycin group had 191 cases, once daily for 5 consecutive days, the first time 0.5g, after each 0.25 g; Cefaclor group had 81 cases, once 0.5 g, 3 times a day for 10 consecutive days. Clinical cure and improvement rates in both groups were 96% and 94%, respectively, while the bacteriological clearance rate was 88%. |
In Huashan Hospital, Shanghai Medical University, 110 patients with respiratory tract infections were oral administration of the product, the total effective rate was 93.6%, bacterial clearance rate was 91.4%, the incidence of adverse reactions was 5.4%.
The product has an excellent effect on the genitourinary system infections caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma. Shanghai Dermatology Prevention Centre used this product to treat patients with non-gonococcal urethritis and gonorrhea, including 30 cases of chlamydia infection, 19 cases of mycoplasma infection, 28 cases of Neisseria gonorrhoeae infection, and oral administration, a single dose 1 g. The cure rates were 100%, 85%, 96.5%, respectively, and total effective rate was 100%.
Previous studies suggested that as for people with high risk of cardiovascular, Azithromycin can increase the risk of cardiovascular mortality. But research in the real world population is lacked. Therefore, there is a large-scale population study in the real world. This is a 18-64-year-old national historical cohort study in Denmark, which is related to information including the prescription registration database, causes of death in patients, and general condition of the patient in 1997 to 2010, etc. The use of Azithromycin up to 110 million treatment courses and not use of antibiotics population controls (1: 1) were evaluated. In addition, compared with 7.36 million passengers using penicillin V (also based on propensity score matching), causes of death from cardiovascular were observed.
The results showed that the use of Azithromycin and not use any antibiotics population significantly increased the risk of cardiovascular death (RR: 2.85, 95CI: 1.13 - 7.24). In the Azithromycin group, 17 patients died. In the penicillin V group, 146 patients died (RR: 0.93,95% CI: 0.56-1.55). Azithromycin does not increase the risk of cardiovascular death in young and elderly patients.
|Chemical properties||White crystals. Melting point 113--115 ℃. [Α] D20-37 ° (C = 1, chloroform).|
|Uses||Macrolide antibiotic, 15-membered nitrogen-containing heterocyclic, antibacterial mechanism is similar to Erythromycin, but antibacterial spectrum is broader. The antibacterial activity of Gram-positive bacteria is stronger. As for Gram-negative bacteria such as Haemophilus influenzae, Salmonella, E. coli, Shigella bacteria, it have strong antibacterial activity. And it is acid stable and well tolerated. It has a very good therapeutic effect on respiratory tract infections, skin and soft tissue infections, sexually transmitted diseases which are caused by sensitive bacteria.|
|Production methods||Using Erythromycin A as raw material, after oximation, under the action of hydrochloric acid, Beckmann rearrangement is performed, followed by dehydration, reduction, methylation , and Azithromycin is obtained.|
|Chemical Properties||White Crystalline Powder|
|Usage||Labelled Azithromycin, a semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial.|
|Usage||Azithromycin is a semi-synthetic, ring-expanded erythromycin, produced by a Beckmann rearrangement of erythromycin oxime and reduction to the imine ether, followed by reductive methylation. Azithromycin was the first of the azalides and was designed to improve stability and biological half-life of erythromycin A, as well as improve activity against Gram negative bacteria. Since its discovery in 1980 by Djokic and co-workers, azithromycin has enjoyed considerable therapeutic success.|
|Usage||Azithromycin is a semi-synthetic, ring-expanded erythromycin produced by a Beckmann rearrangement of erythromycin oxime and reduction to the imine ether, followed by reductive methylation. Azithromycin was the first of the azalides and was designed to improve the stability and biological half-life of erythromycin A, as well as improve activity against Gram negative bacteria. Since its discovery in 1980 by Djokic and co-workers, azithromycin has enjoyed considerable therapeutic success.|
|Usage||Labeled Azithromycin, Intended for use as an internal standard for the quantification of Azithromycin by GC- or LC-mass spectrometry|
|Biological Activity||Macrolide antibiotic. Inhibits 50S ribosomal subunit formation and elongation at transpeptidation step in gram-positive and gram-negative organisms. Orally active with improved pharmacokinetics over erythromycin in mouse models.|
|Azithromycin Preparation Products And Raw materials|